Circulating level of CTRP1 in patients with nonalcoholic fatty liver disease (NAFLD): is it through insulin resistance?
Nonalcoholic fatty liver disease (NAFLD) is considered as one of the most common liver diseases. It is robustly linked to obesity and insulin resistance and is regarded as hepatic manifestation of metabolic syndrome (MetS). Adipokines are involved in the pathophysiology of liver diseases. The aim of...
Gespeichert in:
| Veröffentlicht in: | PloS one 2015-03, Vol.10 (3), p.e0118650-e0118650 |
|---|---|
| Hauptverfasser: | , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | e0118650 |
|---|---|
| container_issue | 3 |
| container_start_page | e0118650 |
| container_title | PloS one |
| container_volume | 10 |
| creator | Shabani, Parisa Naeimi Khaledi, H Beigy, Maani Emamgholipour, Solaleh Parvaz, Eskandar Poustchi, Hossein Doosti, Mahmood |
| description | Nonalcoholic fatty liver disease (NAFLD) is considered as one of the most common liver diseases. It is robustly linked to obesity and insulin resistance and is regarded as hepatic manifestation of metabolic syndrome (MetS). Adipokines are involved in the pathophysiology of liver diseases. The aim of this study was to evaluate the plasma concentrations of CTRP1 (complement-C1q TNF-related protein 1) in 22 patients with NAFLD, 22 patients with type 2 diabetes mellitus (T2DM), 22 patients with NAFLD+T2DM and 21 healthy controls, as well as their correlation with the level of metabolic and hepatic parameters. Plasma concentration of CTRP1 was measured with ELISA method. Plasma concentration of CTRP1 in patients with NAFLD, T2DM and NAFLD+T2DM were significantly higher than healthy subjects (p |
| doi_str_mv | 10.1371/journal.pone.0118650 |
| format | Article |
| fullrecord | <record><control><sourceid>gale_plos_</sourceid><recordid>TN_cdi_plos_journals_1663346879</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A422026565</galeid><doaj_id>oai_doaj_org_article_5e923f9047f449b58cc25b5f27ced3b3</doaj_id><sourcerecordid>A422026565</sourcerecordid><originalsourceid>FETCH-LOGICAL-c692t-f1e5af45fe80afe0feab0c5d575f2b5abae97d2a08ffbc8f4c8a06df3696b3053</originalsourceid><addsrcrecordid>eNqNk9Fu0zAUhiMEYmPwBggsIaHtosWJYyfhAlQVBpUqhsbg1nKc48aVGxfb6djb467Z1KJdIF_Ysr_zH5_fPknyMsXjlBTpu6XtXSfMeG07GOM0LRnFj5LjtCLZiGWYPN5bHyXPvF9iTEnJ2NPkKKMFK8oSHyfXU-1kb0TQ3QIZ2IBBVqHp1eX3FOkOreMBdMGjax1a1NmYUNrWGi2REiHcIKM34FCjPQgP6PTb5Hz-6ew90h7pgELrbL9oo5DvTVRz4LUPopPw8XnyRAnj4cUwnyQ_zz9fTb-O5hdfZtPJfCRZlYWRSoEKlVMFJRYKsAJRY0kbWlCV1VTUAqqiyQQulaplqXJZCswaRVjFahLrPUle73TXxno-eOZ5yhghOSuLKhKzHdFYseRrp1fC3XArNL_dsG7BhQtaGuAUqoyoCueFyvOqpqWUGa3jTQoJDalJ1PowZOvrFTQyWueEORA9POl0yxd2w3NCy6pIo8DpIODs7x584CvtJRgjOrD97b3zLC0wLSP65h_04eoGaiFiAbpTNuaVW1E-ybMMZ4yyrUvjB6g4GlhpGT-Y0nH_IODsICAyAf6Ehei957Mfl__PXvw6ZN_usS0IE1pvTR-07fwhmO9A6az3DtS9ySnm2_64c4Nv-4MP_RHDXu0_0H3QXUOQv6whC-c</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1663346879</pqid></control><display><type>article</type><title>Circulating level of CTRP1 in patients with nonalcoholic fatty liver disease (NAFLD): is it through insulin resistance?</title><source>MEDLINE</source><source>DOAJ Directory of Open Access Journals</source><source>Public Library of Science (PLoS)</source><source>EZB-FREE-00999 freely available EZB journals</source><source>PubMed Central</source><source>Free Full-Text Journals in Chemistry</source><creator>Shabani, Parisa ; Naeimi Khaledi, H ; Beigy, Maani ; Emamgholipour, Solaleh ; Parvaz, Eskandar ; Poustchi, Hossein ; Doosti, Mahmood</creator><contributor>Vinciguerra, Manlio</contributor><creatorcontrib>Shabani, Parisa ; Naeimi Khaledi, H ; Beigy, Maani ; Emamgholipour, Solaleh ; Parvaz, Eskandar ; Poustchi, Hossein ; Doosti, Mahmood ; Vinciguerra, Manlio</creatorcontrib><description>Nonalcoholic fatty liver disease (NAFLD) is considered as one of the most common liver diseases. It is robustly linked to obesity and insulin resistance and is regarded as hepatic manifestation of metabolic syndrome (MetS). Adipokines are involved in the pathophysiology of liver diseases. The aim of this study was to evaluate the plasma concentrations of CTRP1 (complement-C1q TNF-related protein 1) in 22 patients with NAFLD, 22 patients with type 2 diabetes mellitus (T2DM), 22 patients with NAFLD+T2DM and 21 healthy controls, as well as their correlation with the level of metabolic and hepatic parameters. Plasma concentration of CTRP1 was measured with ELISA method. Plasma concentration of CTRP1 in patients with NAFLD, T2DM and NAFLD+T2DM were significantly higher than healthy subjects (p<0.0001). Moreover, we observed significant positive correlations between plasma level of CTRP1 and fasting blood glucose (FBG) (p<0.001), homeostasis model assessment of insulin resistance (HOMA-IR) (p<0.001), body mass index (BMI) (p = 0.001), alanine amino transferase (ALT) (p = 0.002), gamma glutamyl transferase (γ-GT) (p<0.001) and liver stiffness (LS) (p<0.001). Our results indicate the strong association of CTRP1 with insulin resistance in NAFLD. Also, it seems that CTRP1 can be considered as an emerging biomarker for NAFLD, however, more studies are necessary to unravel the role of CTRP1 in NAFLD pathogenesis.</description><identifier>ISSN: 1932-6203</identifier><identifier>EISSN: 1932-6203</identifier><identifier>DOI: 10.1371/journal.pone.0118650</identifier><identifier>PMID: 25767880</identifier><language>eng</language><publisher>United States: Public Library of Science</publisher><subject>Alanine ; Alcohol use ; Biochemistry ; Biomarkers ; Blood glucose ; Body mass ; Body mass index ; Body size ; Cardiovascular disease ; Case-Control Studies ; Cholesterol ; Complement component C1q ; Coronary vessels ; Correlation ; Diabetes ; Diabetes mellitus ; Diabetes mellitus (non-insulin dependent) ; Diabetes Mellitus, Type 2 - blood ; Diabetes Mellitus, Type 2 - complications ; Diabetes Mellitus, Type 2 - metabolism ; Diabetes therapy ; Disease resistance ; Enzyme-linked immunosorbent assay ; Fasting ; Fatty liver ; Glucose ; Hepatitis ; Homeostasis ; Humans ; Hypoglycemic agents ; Insulin ; Insulin Resistance ; Liver ; Liver - metabolism ; Liver - pathology ; Liver diseases ; Medicine ; Metabolic syndrome ; Metabolism ; Middle Aged ; Non-alcoholic Fatty Liver Disease - blood ; Non-alcoholic Fatty Liver Disease - complications ; Non-alcoholic Fatty Liver Disease - metabolism ; Non-alcoholic Fatty Liver Disease - pathology ; Obesity ; Pathogenesis ; Patients ; Proteins ; Proteins - metabolism ; Rodents ; Stiffness ; Studies ; Tumor necrosis factor ; Tumor necrosis factor-TNF</subject><ispartof>PloS one, 2015-03, Vol.10 (3), p.e0118650-e0118650</ispartof><rights>COPYRIGHT 2015 Public Library of Science</rights><rights>2015 Shabani et al. This is an open access article distributed under the terms of the Creative Commons Attribution License: http://creativecommons.org/licenses/by/4.0/ (the “License”), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>2015 Shabani et al 2015 Shabani et al</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c692t-f1e5af45fe80afe0feab0c5d575f2b5abae97d2a08ffbc8f4c8a06df3696b3053</citedby><cites>FETCH-LOGICAL-c692t-f1e5af45fe80afe0feab0c5d575f2b5abae97d2a08ffbc8f4c8a06df3696b3053</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC4358971/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC4358971/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,724,777,781,861,882,2096,2915,23847,27905,27906,53772,53774,79349,79350</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/25767880$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><contributor>Vinciguerra, Manlio</contributor><creatorcontrib>Shabani, Parisa</creatorcontrib><creatorcontrib>Naeimi Khaledi, H</creatorcontrib><creatorcontrib>Beigy, Maani</creatorcontrib><creatorcontrib>Emamgholipour, Solaleh</creatorcontrib><creatorcontrib>Parvaz, Eskandar</creatorcontrib><creatorcontrib>Poustchi, Hossein</creatorcontrib><creatorcontrib>Doosti, Mahmood</creatorcontrib><title>Circulating level of CTRP1 in patients with nonalcoholic fatty liver disease (NAFLD): is it through insulin resistance?</title><title>PloS one</title><addtitle>PLoS One</addtitle><description>Nonalcoholic fatty liver disease (NAFLD) is considered as one of the most common liver diseases. It is robustly linked to obesity and insulin resistance and is regarded as hepatic manifestation of metabolic syndrome (MetS). Adipokines are involved in the pathophysiology of liver diseases. The aim of this study was to evaluate the plasma concentrations of CTRP1 (complement-C1q TNF-related protein 1) in 22 patients with NAFLD, 22 patients with type 2 diabetes mellitus (T2DM), 22 patients with NAFLD+T2DM and 21 healthy controls, as well as their correlation with the level of metabolic and hepatic parameters. Plasma concentration of CTRP1 was measured with ELISA method. Plasma concentration of CTRP1 in patients with NAFLD, T2DM and NAFLD+T2DM were significantly higher than healthy subjects (p<0.0001). Moreover, we observed significant positive correlations between plasma level of CTRP1 and fasting blood glucose (FBG) (p<0.001), homeostasis model assessment of insulin resistance (HOMA-IR) (p<0.001), body mass index (BMI) (p = 0.001), alanine amino transferase (ALT) (p = 0.002), gamma glutamyl transferase (γ-GT) (p<0.001) and liver stiffness (LS) (p<0.001). Our results indicate the strong association of CTRP1 with insulin resistance in NAFLD. Also, it seems that CTRP1 can be considered as an emerging biomarker for NAFLD, however, more studies are necessary to unravel the role of CTRP1 in NAFLD pathogenesis.</description><subject>Alanine</subject><subject>Alcohol use</subject><subject>Biochemistry</subject><subject>Biomarkers</subject><subject>Blood glucose</subject><subject>Body mass</subject><subject>Body mass index</subject><subject>Body size</subject><subject>Cardiovascular disease</subject><subject>Case-Control Studies</subject><subject>Cholesterol</subject><subject>Complement component C1q</subject><subject>Coronary vessels</subject><subject>Correlation</subject><subject>Diabetes</subject><subject>Diabetes mellitus</subject><subject>Diabetes mellitus (non-insulin dependent)</subject><subject>Diabetes Mellitus, Type 2 - blood</subject><subject>Diabetes Mellitus, Type 2 - complications</subject><subject>Diabetes Mellitus, Type 2 - metabolism</subject><subject>Diabetes therapy</subject><subject>Disease resistance</subject><subject>Enzyme-linked immunosorbent assay</subject><subject>Fasting</subject><subject>Fatty liver</subject><subject>Glucose</subject><subject>Hepatitis</subject><subject>Homeostasis</subject><subject>Humans</subject><subject>Hypoglycemic agents</subject><subject>Insulin</subject><subject>Insulin Resistance</subject><subject>Liver</subject><subject>Liver - metabolism</subject><subject>Liver - pathology</subject><subject>Liver diseases</subject><subject>Medicine</subject><subject>Metabolic syndrome</subject><subject>Metabolism</subject><subject>Middle Aged</subject><subject>Non-alcoholic Fatty Liver Disease - blood</subject><subject>Non-alcoholic Fatty Liver Disease - complications</subject><subject>Non-alcoholic Fatty Liver Disease - metabolism</subject><subject>Non-alcoholic Fatty Liver Disease - pathology</subject><subject>Obesity</subject><subject>Pathogenesis</subject><subject>Patients</subject><subject>Proteins</subject><subject>Proteins - metabolism</subject><subject>Rodents</subject><subject>Stiffness</subject><subject>Studies</subject><subject>Tumor necrosis factor</subject><subject>Tumor necrosis factor-TNF</subject><issn>1932-6203</issn><issn>1932-6203</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2015</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><sourceid>DOA</sourceid><recordid>eNqNk9Fu0zAUhiMEYmPwBggsIaHtosWJYyfhAlQVBpUqhsbg1nKc48aVGxfb6djb467Z1KJdIF_Ysr_zH5_fPknyMsXjlBTpu6XtXSfMeG07GOM0LRnFj5LjtCLZiGWYPN5bHyXPvF9iTEnJ2NPkKKMFK8oSHyfXU-1kb0TQ3QIZ2IBBVqHp1eX3FOkOreMBdMGjax1a1NmYUNrWGi2REiHcIKM34FCjPQgP6PTb5Hz-6ew90h7pgELrbL9oo5DvTVRz4LUPopPw8XnyRAnj4cUwnyQ_zz9fTb-O5hdfZtPJfCRZlYWRSoEKlVMFJRYKsAJRY0kbWlCV1VTUAqqiyQQulaplqXJZCswaRVjFahLrPUle73TXxno-eOZ5yhghOSuLKhKzHdFYseRrp1fC3XArNL_dsG7BhQtaGuAUqoyoCueFyvOqpqWUGa3jTQoJDalJ1PowZOvrFTQyWueEORA9POl0yxd2w3NCy6pIo8DpIODs7x584CvtJRgjOrD97b3zLC0wLSP65h_04eoGaiFiAbpTNuaVW1E-ybMMZ4yyrUvjB6g4GlhpGT-Y0nH_IODsICAyAf6Ehei957Mfl__PXvw6ZN_usS0IE1pvTR-07fwhmO9A6az3DtS9ySnm2_64c4Nv-4MP_RHDXu0_0H3QXUOQv6whC-c</recordid><startdate>20150313</startdate><enddate>20150313</enddate><creator>Shabani, Parisa</creator><creator>Naeimi Khaledi, H</creator><creator>Beigy, Maani</creator><creator>Emamgholipour, Solaleh</creator><creator>Parvaz, Eskandar</creator><creator>Poustchi, Hossein</creator><creator>Doosti, Mahmood</creator><general>Public Library of Science</general><general>Public Library of Science (PLoS)</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>IOV</scope><scope>ISR</scope><scope>3V.</scope><scope>7QG</scope><scope>7QL</scope><scope>7QO</scope><scope>7RV</scope><scope>7SN</scope><scope>7SS</scope><scope>7T5</scope><scope>7TG</scope><scope>7TM</scope><scope>7U9</scope><scope>7X2</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8FD</scope><scope>8FE</scope><scope>8FG</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABJCF</scope><scope>ABUWG</scope><scope>AEUYN</scope><scope>AFKRA</scope><scope>ARAPS</scope><scope>ATCPS</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BGLVJ</scope><scope>BHPHI</scope><scope>C1K</scope><scope>CCPQU</scope><scope>D1I</scope><scope>DWQXO</scope><scope>FR3</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>H94</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>KB.</scope><scope>KB0</scope><scope>KL.</scope><scope>L6V</scope><scope>LK8</scope><scope>M0K</scope><scope>M0S</scope><scope>M1P</scope><scope>M7N</scope><scope>M7P</scope><scope>M7S</scope><scope>NAPCQ</scope><scope>P5Z</scope><scope>P62</scope><scope>P64</scope><scope>PATMY</scope><scope>PDBOC</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>PTHSS</scope><scope>PYCSY</scope><scope>RC3</scope><scope>7X8</scope><scope>5PM</scope><scope>DOA</scope></search><sort><creationdate>20150313</creationdate><title>Circulating level of CTRP1 in patients with nonalcoholic fatty liver disease (NAFLD): is it through insulin resistance?</title><author>Shabani, Parisa ; Naeimi Khaledi, H ; Beigy, Maani ; Emamgholipour, Solaleh ; Parvaz, Eskandar ; Poustchi, Hossein ; Doosti, Mahmood</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c692t-f1e5af45fe80afe0feab0c5d575f2b5abae97d2a08ffbc8f4c8a06df3696b3053</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2015</creationdate><topic>Alanine</topic><topic>Alcohol use</topic><topic>Biochemistry</topic><topic>Biomarkers</topic><topic>Blood glucose</topic><topic>Body mass</topic><topic>Body mass index</topic><topic>Body size</topic><topic>Cardiovascular disease</topic><topic>Case-Control Studies</topic><topic>Cholesterol</topic><topic>Complement component C1q</topic><topic>Coronary vessels</topic><topic>Correlation</topic><topic>Diabetes</topic><topic>Diabetes mellitus</topic><topic>Diabetes mellitus (non-insulin dependent)</topic><topic>Diabetes Mellitus, Type 2 - blood</topic><topic>Diabetes Mellitus, Type 2 - complications</topic><topic>Diabetes Mellitus, Type 2 - metabolism</topic><topic>Diabetes therapy</topic><topic>Disease resistance</topic><topic>Enzyme-linked immunosorbent assay</topic><topic>Fasting</topic><topic>Fatty liver</topic><topic>Glucose</topic><topic>Hepatitis</topic><topic>Homeostasis</topic><topic>Humans</topic><topic>Hypoglycemic agents</topic><topic>Insulin</topic><topic>Insulin Resistance</topic><topic>Liver</topic><topic>Liver - metabolism</topic><topic>Liver - pathology</topic><topic>Liver diseases</topic><topic>Medicine</topic><topic>Metabolic syndrome</topic><topic>Metabolism</topic><topic>Middle Aged</topic><topic>Non-alcoholic Fatty Liver Disease - blood</topic><topic>Non-alcoholic Fatty Liver Disease - complications</topic><topic>Non-alcoholic Fatty Liver Disease - metabolism</topic><topic>Non-alcoholic Fatty Liver Disease - pathology</topic><topic>Obesity</topic><topic>Pathogenesis</topic><topic>Patients</topic><topic>Proteins</topic><topic>Proteins - metabolism</topic><topic>Rodents</topic><topic>Stiffness</topic><topic>Studies</topic><topic>Tumor necrosis factor</topic><topic>Tumor necrosis factor-TNF</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Shabani, Parisa</creatorcontrib><creatorcontrib>Naeimi Khaledi, H</creatorcontrib><creatorcontrib>Beigy, Maani</creatorcontrib><creatorcontrib>Emamgholipour, Solaleh</creatorcontrib><creatorcontrib>Parvaz, Eskandar</creatorcontrib><creatorcontrib>Poustchi, Hossein</creatorcontrib><creatorcontrib>Doosti, Mahmood</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Gale In Context: Opposing Viewpoints</collection><collection>Gale In Context: Science</collection><collection>ProQuest Central (Corporate)</collection><collection>Animal Behavior Abstracts</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Biotechnology Research Abstracts</collection><collection>Nursing & Allied Health Database</collection><collection>Ecology Abstracts</collection><collection>Entomology Abstracts (Full archive)</collection><collection>Immunology Abstracts</collection><collection>Meteorological & Geoastrophysical Abstracts</collection><collection>Nucleic Acids Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Agricultural Science Collection</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>Technology Research Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Technology Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Materials Science & Engineering Collection</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest One Sustainability</collection><collection>ProQuest Central UK/Ireland</collection><collection>Advanced Technologies & Aerospace Collection</collection><collection>Agricultural & Environmental Science Collection</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Technology Collection</collection><collection>Natural Science Collection (ProQuest)</collection><collection>Environmental Sciences and Pollution Management</collection><collection>ProQuest One Community College</collection><collection>ProQuest Materials Science Collection</collection><collection>ProQuest Central Korea</collection><collection>Engineering Research Database</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Materials Science Database</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>Meteorological & Geoastrophysical Abstracts - Academic</collection><collection>ProQuest Engineering Collection</collection><collection>ProQuest Biological Science Collection</collection><collection>Agricultural Science Database</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Biological Science Database</collection><collection>Engineering Database</collection><collection>Nursing & Allied Health Premium</collection><collection>Advanced Technologies & Aerospace Database</collection><collection>ProQuest Advanced Technologies & Aerospace Collection</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>Environmental Science Database</collection><collection>Materials Science Collection</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>Engineering Collection</collection><collection>Environmental Science Collection</collection><collection>Genetics Abstracts</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><collection>DOAJ Directory of Open Access Journals</collection><jtitle>PloS one</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Shabani, Parisa</au><au>Naeimi Khaledi, H</au><au>Beigy, Maani</au><au>Emamgholipour, Solaleh</au><au>Parvaz, Eskandar</au><au>Poustchi, Hossein</au><au>Doosti, Mahmood</au><au>Vinciguerra, Manlio</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Circulating level of CTRP1 in patients with nonalcoholic fatty liver disease (NAFLD): is it through insulin resistance?</atitle><jtitle>PloS one</jtitle><addtitle>PLoS One</addtitle><date>2015-03-13</date><risdate>2015</risdate><volume>10</volume><issue>3</issue><spage>e0118650</spage><epage>e0118650</epage><pages>e0118650-e0118650</pages><issn>1932-6203</issn><eissn>1932-6203</eissn><abstract>Nonalcoholic fatty liver disease (NAFLD) is considered as one of the most common liver diseases. It is robustly linked to obesity and insulin resistance and is regarded as hepatic manifestation of metabolic syndrome (MetS). Adipokines are involved in the pathophysiology of liver diseases. The aim of this study was to evaluate the plasma concentrations of CTRP1 (complement-C1q TNF-related protein 1) in 22 patients with NAFLD, 22 patients with type 2 diabetes mellitus (T2DM), 22 patients with NAFLD+T2DM and 21 healthy controls, as well as their correlation with the level of metabolic and hepatic parameters. Plasma concentration of CTRP1 was measured with ELISA method. Plasma concentration of CTRP1 in patients with NAFLD, T2DM and NAFLD+T2DM were significantly higher than healthy subjects (p<0.0001). Moreover, we observed significant positive correlations between plasma level of CTRP1 and fasting blood glucose (FBG) (p<0.001), homeostasis model assessment of insulin resistance (HOMA-IR) (p<0.001), body mass index (BMI) (p = 0.001), alanine amino transferase (ALT) (p = 0.002), gamma glutamyl transferase (γ-GT) (p<0.001) and liver stiffness (LS) (p<0.001). Our results indicate the strong association of CTRP1 with insulin resistance in NAFLD. Also, it seems that CTRP1 can be considered as an emerging biomarker for NAFLD, however, more studies are necessary to unravel the role of CTRP1 in NAFLD pathogenesis.</abstract><cop>United States</cop><pub>Public Library of Science</pub><pmid>25767880</pmid><doi>10.1371/journal.pone.0118650</doi><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1932-6203 |
| ispartof | PloS one, 2015-03, Vol.10 (3), p.e0118650-e0118650 |
| issn | 1932-6203 1932-6203 |
| language | eng |
| recordid | cdi_plos_journals_1663346879 |
| source | MEDLINE; DOAJ Directory of Open Access Journals; Public Library of Science (PLoS); EZB-FREE-00999 freely available EZB journals; PubMed Central; Free Full-Text Journals in Chemistry |
| subjects | Alanine Alcohol use Biochemistry Biomarkers Blood glucose Body mass Body mass index Body size Cardiovascular disease Case-Control Studies Cholesterol Complement component C1q Coronary vessels Correlation Diabetes Diabetes mellitus Diabetes mellitus (non-insulin dependent) Diabetes Mellitus, Type 2 - blood Diabetes Mellitus, Type 2 - complications Diabetes Mellitus, Type 2 - metabolism Diabetes therapy Disease resistance Enzyme-linked immunosorbent assay Fasting Fatty liver Glucose Hepatitis Homeostasis Humans Hypoglycemic agents Insulin Insulin Resistance Liver Liver - metabolism Liver - pathology Liver diseases Medicine Metabolic syndrome Metabolism Middle Aged Non-alcoholic Fatty Liver Disease - blood Non-alcoholic Fatty Liver Disease - complications Non-alcoholic Fatty Liver Disease - metabolism Non-alcoholic Fatty Liver Disease - pathology Obesity Pathogenesis Patients Proteins Proteins - metabolism Rodents Stiffness Studies Tumor necrosis factor Tumor necrosis factor-TNF |
| title | Circulating level of CTRP1 in patients with nonalcoholic fatty liver disease (NAFLD): is it through insulin resistance? |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-20T03%3A52%3A11IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_plos_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Circulating%20level%20of%20CTRP1%20in%20patients%20with%20nonalcoholic%20fatty%20liver%20disease%20(NAFLD):%20is%20it%20through%20insulin%20resistance?&rft.jtitle=PloS%20one&rft.au=Shabani,%20Parisa&rft.date=2015-03-13&rft.volume=10&rft.issue=3&rft.spage=e0118650&rft.epage=e0118650&rft.pages=e0118650-e0118650&rft.issn=1932-6203&rft.eissn=1932-6203&rft_id=info:doi/10.1371/journal.pone.0118650&rft_dat=%3Cgale_plos_%3EA422026565%3C/gale_plos_%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1663346879&rft_id=info:pmid/25767880&rft_galeid=A422026565&rft_doaj_id=oai_doaj_org_article_5e923f9047f449b58cc25b5f27ced3b3&rfr_iscdi=true |